CBT 008
Alternative Names: CBT-008Latest Information Update: 10 Feb 2023
At a glance
- Originator Cloudbreak therapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Meibomianitis
Most Recent Events
- 19 Jan 2023 Cloudbreak Therapeutics completes a phase II trial in Meibomianitis in USA (Ophthalmic) (NCT05261386)
- 24 Mar 2022 Phase-II clinical trials in Meibomianitis in USA (Ophthalmic) (NCT05261386)
- 02 Mar 2022 Cloudbreak Therapeutics plans to initiate a phase II trial in Meibomianitis in USA (Ophthalmic) in March 2022 (NCT05261386)